PTC Therapeutics ( (PTCT) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PTC Therapeutics’ stock has come under pressure as investors grow wary of increased insider selling, which is seen as a warning sign despite improving fundamentals. This caution contrasts with Wall Street’s more upbeat view: several analysts have recently raised their price targets and turned more positive on the stock after PTC reported stronger quarterly results and issued optimistic guidance for both product and royalty revenues. Their bullishness is also supported by improving sentiment across the biotech sector—driven by expectations of more mergers and acquisitions, easing concerns over drug pricing, and what they view as an underappreciated market opportunity in phenylketonuria, along with reduced risk in parts of PTC’s drug pipeline.
More about PTC Therapeutics
YTD Price Performance: 0.36%
Average Trading Volume: 1,609,892
Technical Sentiment Signal: Buy
Current Market Cap: $6.12B
For further insights into PTCT stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.